# US 2012/0251554 A1 · Anti-cd33 antibodies and use thereof for immunotargeting in treating cd33-associated illnesses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251554 A1
- Document ID: US20120251554A1
- Status: Published application
- Kind: A1
- Application number: 13/497,800
- Filed: 2010-09-22
- Published: 2012-10-04
- Earliest claimed: 2009-09-25
- Assignees: Technische UniversitäT Dresden
- Inventors: Michael Bachmann; Slava Stamova
- Web page: https://patentgrep.com/patent/US20120251554A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to antibodies to the tumor-associated antigen CD33 and to the use thereof for immunotargeting CD33-positive cells. The antibodies according to the invention are suitable for use in the field of medicine, pharmaceuticals, and biomedical research. According to the invention, the aim is achieved by means of novel anti-CD33 antibodies comprising the complementary determining regions (CDRs) defined in the claim. The antibodies according to the invention are characterized by a high affinity for human CD33, of the order of magnitude of 1010 mol/l. The CDR sequences according to the invention are suitable in particular for producing recombinant fragments (such as scFv fragments or bispecific antibodies) and for immunotargeting, due to the high affinity thereof. The invention further relates to the use of an antibody according to the invention for producing a medication for therapeutic and/or diagnostic application for illnesses associated with the expression of CD33, particularly for acute myeloid leukemia (AML). The invention thus also comprises a pharmaceutical composition comprising one or more antibodies according to the invention in association with a pharmaceutically acceptable thinning agent or carrier.

## Claims

### Claim 1

Anti-CD33 antibody containing regions determined by complementarity (complementary determining regions, CDRs), characterized in that the CDRs comprise the following sequences:
a) variable region of the heavy chain (VH)
CDR1 DYVVH,
CDR2 YINPYNDGTKYNEKFKG,
CDR3 DYRYEVYGMDY,
and
b) variable region of the light chain (VL):
CDR1 TASSSVNYIH,
CDR2 TSKVAS,
CDR3 QQWRSYPLT.

### Claim 2 (depends on 1)

Antibody according to claim 1, containing the following, optionally humanized, structure:
a variable region of the heavy chain with the sequence according to SEQ ID NO. 13
and a variable region of the light chain with a sequence according to SEQ ID NO. 14.

### Claim 3 (depends on 1)

Antibody according to claim 1, containing additionally at least one of the following structures
a constant region of a heavy chain of a human IgG,
a region CL of the human kappa light chain and/or
a human IgG3 hinge region,
optionally in the form of a F(ab′)2 fragment.

### Claim 4 (depends on 1)

Antibody according to claim 1 in the form of an scFv fragment or in the form of a F(ab′)2 fragment.

### Claim 5 (depends on 1)

Antibody according to claim 1, characterized in that it is conjugated with an effector group or a further antibody or antibody fragment that is specific to another antigen than CD33.

### Claim 6 (depends on 5)

Antibody according to claim 5, wherein the effector group is selected from toxins, enzymes, co-stimulating molecules, radionuclides and nucleic acids, optionally in the form of a fusion protein.

### Claim 7 (depends on 1)

Antibody according to claim 1, characterized in that it is conjugated with a ligand that binds specifically to effector cells and in this way affects their activity.

### Claim 8 (depends on 1)

Nucleic acid sequence coding for an antibody according to claim 1.

### Claim 9 (depends on 8)

Vector containing a nucleic acid sequence according to claim 8.

### Claim 10 (depends on 8)

Host cell containing a nucleic acid sequence according to claim 8 or a vector containing a nucleic acid sequence according to claim 8.

### Claim 11 (depends on 1)

Pharmaceutical composition, containing an antibody according to claim 1 in association with a pharmaceutically acceptable dilution agent or carrier.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

Method for preparing an antibody according to claim 1, in which:
a. a host cell or a non-human host organism that contains a nucleic acid sequence coding for an antibody according to claim 1 or that contains a vector containing a nucleic acid sequence coding for an antibody according to claim 1 is exposed to conditions under which an expression and optionally a secretion of the antibody takes place, and
b. the antibody is at least partially purified.

### Claim 14 (depends on 8)

Non-human host organism containing a nucleic acid sequence according to claim 8 or a vector containing a nucleic acid sequence according to claim 8.
